You are here: Industry Insights > Eisai

News List

Eisai, Merck get FDA approval for LENVIMA capsules to treat HCC biospectrumasia
August 20, 2018
Marks second approval under Eisai-Merck global collaboration to co-develop and co-commercialize LENVIMA, following Japan in March 2018
Eisai inks deal with Taiwan, China's CY Biotech biospectrumasia
August 10, 2018
The deal grants CY Biotech with exclusive development and marketing rights for its anti-obesity agent lorcaserin in China
Eisai to market anti-Obesity agent in China through CY Biotech biospectrumasia
August 01, 2018
Eisai will receive a one-time contractual payment and milestone payments dependent upon acquisition of regulatory approval. In addition, Eisai has the option rights to co-promote lorcaserin with CYB in China
Eisai and Biogen to move forward with Alzheimer’s drug expressbpd
July 25, 2018
Eisai and Biogen will move forward with late-stage clinical trials of their Alzheimer’s disease drug, BAN2401.
Biogen and Eisai’s previously bleak Alzheimer’s study comes back with positive results fiercebiotech
July 09, 2018
A phase 2 Alzheimer’s trial—once nearly consigned to the heap of disappointing attempts against the disease—has re-emerged with new positive results
Eisai Launches Dementia Discovery Center contractpharma
June 19, 2018
Eisai Inc. announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human genetics to develop next-generation medicines for Alzheimer's disease (AD) and other dementias.
Eisai, Purdue reveal eye-opening data for sleep drug lemborexant fiercebiotech
June 11, 2018
Eisai and Purdue Pharma have presented new clinical trial results of their dual orexin receptor antagonist lemborexant, which they think could become a new force in the sleep disorder market.
Eisai partners with Chong Kun Dang for drug sales biospectrumasia
June 06, 2018
Chong Kun Dang will focus on sales and marketing for clinics, and Eisai Korea, for general hospitals.
Eisai forms partnership to find new tuberculosis treatment pharmafile
April 16, 2018
Eisai has teamed up with the Broad Institute, the Mycobacteria Research Laboratories at Colorado State University and the University of Chicago, entering into a new research partnership to develop a new treatment for tuberculosis (TB).
Eisai, Nichi-Iko Pharma enters strategic partnership biospectrumasia
March 30, 2018
Both companies will promote cooperation in building Eisai's Total Inclusive Ecosystem as well as collaboration on the active pharmaceutical ingredient (API) business promoted primarily at Eisai's Vizag Plant in India

Previous page 1 2 3 4 5 6 7 8 9 10 Next page